Albiglutide vs. Liraglutide: A Head-to-Head Phase 3 Diabetes Trial
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
Background
Type 2 Diabetes Mellitus is a chronic metabolic condition characterized by high blood sugar levels, often requiring long-term medication. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs effective in managing this condition, improving glycemic control and often aiding weight loss. While several GLP-1 agonists exist, their comparative efficacy and safety profiles, particularly regarding dosing frequency, were not fully established; this study aimed to directly compare the weekly GLP-1 agonist albiglutide with the daily GLP-1 agonist liraglutide.
Study Design
Population
Adult patients with Type 2 Diabetes Mellitus requiring long-term medication.
Intervention
Albiglutide, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist.
Comparator
Liraglutide, a daily glucagon-like peptide-1 (GLP-1) receptor agonist.
Outcome
Comparative efficacy and safety profiles, particularly regarding glycemic control and weight loss.